Get the Stockscreener App
47.04
0.38%
-0.18
After Hours:
46.50
-0.54
-1.15%
Maze Therapeutics Inc stock is traded at $47.04, with a volume of 589.28K.
It is down -0.38% in the last 24 hours and up +17.04% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$47.22
Open:
$47.3
24h Volume:
589.28K
Relative Volume:
1.29
Market Cap:
$2.26B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.03%
1M Performance:
+17.04%
6M Performance:
+242.36%
1Y Performance:
+292.65%
1-Day Range:
$45.51
$47.85
1-Week Range:
$42.79
$48.52
52-Week Range:
$6.71
$49.25
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
47.04 | 2.27B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics Secures New $200 Million Loan Facility - TipRanks
Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock - Defense World
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - aol.com
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock - MarketBeat
Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - The Motley Fool
Maze Therapeutics, Inc. (MAZE): Investor Outlook And 9.88% Potential Upside - DirectorsTalk Interviews
Washington University Takes Position in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com Canada
Equities Analysts Set Expectations for MAZE FY2030 Earnings - MarketBeat
Maze Therapeutics Rings the Closing Bell - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Raised to "Hold" at Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts - MarketBeat
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Strong Buy Ratings Amid Potential 7% Upside - DirectorsTalk Interviews
Retail Surge: What’s the fair value of Maze Therapeutics Inc. stockQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - mfd.ru
First Week of March 20th Options Trading For Maze Therapeutics (MAZE) - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $46.00 - Defense World
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
BTIG Research Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $46.00 - MarketBeat
Maze Therapeutics: An Innovative, Nature-Driven Platform (NASDAQ:MAZE) - Seeking Alpha
Assessing Maze Therapeutics (MAZE) Valuation After Its Recent Share Price Momentum - Sahm
What dividend safety score for Maze Therapeutics Inc. stockInflation Watch & Proven Capital Preservation Tips - Bộ Nội Vụ
Gainers Report: How Maze Therapeutics Inc stock valuations compare to rivals2025 Technical Patterns & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
How Maze Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Final Week & Risk Managed Investment Entry Signals - Улправда
How Maze Therapeutics Inc. stock valuations compare to rivalsStock Surge & Low Risk Profit Maximizing Plans - Улправда
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 25,156 Shares - MarketBeat
Maze Therapeutics (MAZE) Stock Analysis: Exploring a 21.52% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale - TipRanks
How rising interest rates impact Maze Therapeutics Inc. stock2025 Sector Review & Daily Momentum Trading Reports - Улправда
How Maze Therapeutics Inc. stock reacts to oil pricesJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - Улправда
Is Maze Therapeutics Inc. stock trading at a premium valuation2025 Bull vs Bear & Safe Capital Growth Stock Tips - Улправда
What sentiment indicators say about Maze Therapeutics Inc. stockQuarterly Profit Summary & Reliable Price Breakout Alerts - Улправда
Is Maze Therapeutics Inc. stock supported by innovation pipeline2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 412 Shares of Stock - MarketBeat
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BERNSTEIN HAROLD Insider Trades - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 4.9% – Here’s Why - Defense World
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Maze Therapeutics Inc Stock (MAZE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Feb 02 '26 |
Sale |
46.02 |
15,000 |
690,334 |
0 |
| Bachrodt Amy | SVP, Finance |
Feb 02 '26 |
Option Exercise |
10.42 |
5,000 |
52,100 |
17,965 |
| Bachrodt Amy | SVP, Finance |
Feb 02 '26 |
Sale |
46.04 |
5,000 |
230,219 |
12,965 |
| Dandekar Atul | CSBO |
Jan 29 '26 |
Option Exercise |
10.42 |
7,500 |
78,150 |
18,003 |
| Dandekar Atul | CSBO |
Jan 29 '26 |
Sale |
44.27 |
7,500 |
331,990 |
10,503 |
| Bachrodt Amy | SVP, Finance |
Jan 22 '26 |
Option Exercise |
10.42 |
5,000 |
52,100 |
17,965 |
| Bachrodt Amy | SVP, Finance |
Jan 22 '26 |
Sale |
45.52 |
5,000 |
227,612 |
12,965 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):